<DOC>
	<DOCNO>NCT02074345</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity intramuscular TAK-816 healthy Japanese infant .</brief_summary>
	<brief_title>Phase III Study Intramuscular TAK-816 Healthy Infants</brief_title>
	<detailed_description>The vaccine test study call TAK-816 . TAK-816 test evaluate safety immune response intramuscular ( IM ) injection TAK-816 . This study evaluate adverse event seroprotection rate geometric mean titer ( GMT ) anti-polyribosylribitol phosphate ( PRP ) -antibodies participant administer TAK-816 IM . The study enrol 31 participant . All participant receive 3 dos TAK-816 IM 4-week interval part primary vaccination 1 booster vaccination 52 week third dose primary vaccination . This multi-center trial conduct Japan . The overall time participate study 64 week . Participants make multiple visit clinic include final visit 4 week last dose study drug follow-up assessment .</detailed_description>
	<criteria>1 . Healthy Japanese infant . 2 . Male female infant age 26 month ( â‰¥2 &lt; 7 month ) time first dose investigational product ( exclude hospitalize infant ) . 3 . Infants whose parent legal guardian agree cooperate investigator study period . 4 . The legal guardian sign dated write , informed consent form prior initiation study procedure . 1 . Any serious acute illness . 2 . Any underlying cardiovascular , renal , hepatic , hematologic disease , and/or developmental disorder . 3 . History possible Haemophilus influenzae type b ( Hib ) infection . 4 . Previously diagnosed immunodeficiency . 5 . Documented history anaphylaxis ingredient investigational product ( e.g. , diphtheria toxoid ) . 6 . A history convulsion . 7 . Previous administration another Hib vaccine . 8 . Treatment live vaccine 27 day first dose TAK816 inactivate vaccine 6 day dose . 9 . Prior participation clinical study postmarketing clinical study . 10 . Previously receipt blood transfusion , gamma globulin preparation ( except monoclonal antibody product contain component Hib antigen ) , systemic immunosuppressive therapy , systemic corticosteroid , plan receive product study period . 11 . Presence thrombocytopenia coagulopathy . 12 . Children consider ineligible study reason investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug therapy</keyword>
	<keyword>Safety immunogenicity Hib vaccine</keyword>
</DOC>